logo

For the Inventor, By the Inventor

San Jose, CA, United States of America

Ariosa Diagnostics, Inc.


USPTO Granted Patents = 27



Trademarks = 8

Forward Citations = 157

Loading Chart...
Loading Chart...

13 inventors (with patents filed for the assignee):

goldMedal Arnold Oliphant (23 out of 49 patents)

silverMedal Craig Struble (14 out of 21 patents)

bronzeMedal Andrew Sparks (14 out of 21 patents)

4.  John Stuelpnagel (13 out of 15 patents)

5.  Jacob Zahn (10 out of 12 patents)

6.  Ken Song (9 out of 10 patents)

7.  Eric Wang (6 out of 16 patents)

8.  Eric Wang (4 out of 14 patents)

9.  Patrick Bogard (3 out of 4 patents)

10.  Stephanie Huang (3 out of 4 patents)

11.  Kara Juneau (2 out of 3 patents)

12.  Morassa Mohseni (2 out of 2 patents)

13.  Kara Jeneau (1 out of 1 patent)


27 patents:

1. 12195799 - Risk calculation for evaluation of fetal aneuploidy (2025-01-14),
2. 11299772 - Assay systems for genetic analysis (2022-04-12),
3. 11289176 - Determination of copy number variations using binomial probability calculations (2022-03-29),
4. 11270781 - Statistical analysis for non-invasive sex chromosome aneuploidy determination (2022-03-08),
5. 11203786 - Detection of target nucleic acids using hybridization (2021-12-21),
6. 11091807 - Assay systems for genetic analysis (2021-08-17),
7. 11031095 - Assay systems for determination of fetal copy number variation (2021-06-08),
8. 10954566 - Ligation-based detection of genetic variants (2021-03-23),
9. 10907198 - Assay systems for genetic analysis (2021-02-02),
10. 10847250 - Determination of copy number variations using binomial probability calculations (2020-11-24),
11. 10718024 - Risk calculation for evaluation of fetal aneuploidy (2020-07-21),
12. 10718019 - Risk calculation for evaluation of fetal aneuploidy (2020-07-21),
13. 10533223 - Detection of target nucleic acids using hybridization (2020-01-14),
14. 10308981 - Assay systems for determination of source contribution in a sample (2019-06-04),
15. 10289800 - Processes for calculating phased fetal genomic sequences (2019-05-14),
Ariosa Diagnostics, Inc. is a leading molecular diagnostics company specializing in non-invasive prenatal testing (NIPT). Their innovative technologies and tests provide accurate and reliable screening for genetic conditions during pregnancy. With a commitment to advancing clinical care, Ariosa Diagnostics aims to improve patient outcomes and empower healthcare providers with valuable genetic information. Visit their website to learn more about their groundbreaking solutions in prenatal testing.
This text is generated by artificial intelligence and may not be accurate.

logo

Company Badge

USPTO Data Jan 1 1976 - Sep 15 2026

Ariosa Diagnostics, Inc.
27 Patents

#278 in San Jose, CA

#2,927 in California

#12,393 in US

#23,931 in the World

San Jose, CA (US)
San Jose, CA, United States of America

Ariosa Diagnostics, Inc.

Forward Citations = 157

13 inventors:

goldMedal Arnold Oliphant (23 out of 49 patents)

silverMedal Craig Struble (14 out of 21 patents)

bronzeMedal Andrew Sparks (14 out of 21 patents)

4.  John Stuelpnagel (13 out of 15 patents)

5.  Jacob Zahn (10 out of 12 patents)

Please report any incorrect information to [email protected]
Loading…